Charles River Laboratories is rallying in pre-market trading following a successful Investor Day where management raised the 2026 earnings outlook and reaffirmed long-term growth and margin targets for 2030. Investor sentiment is further bolstered by the company's strategic positioning in the cell and gene therapy biomanufacturing market, which is projected to grow at an 11.7% CAGR to reach $8.7 billion by 2031. This positive momentum follows a strong year for the stock, which has delivered a 63.6% return over the past twelve months, and reflects broader confidence in the firm's ability to capitalize on increasing demand for its research and diagnostic services.